TABLE 3.

Immunological, virological, and clinical findings for the 17 patients with CMV infection in the preemptive strategy group^a

QFN-CMV result (time point before the onset of CMV infection)	QFN-CMV result (time point following first CMV DNAemia)	First CMV DNAemia (day post-TX)	Peak CMV DNAemia (IU/ml WB)	Antiviral therapyb	CMV disease
Indeterminate	Indeterminate	23	3,333	Yes	No
Indeterminate	Indeterminate	27	5,810	Yes	No
Indeterminate	Indeterminate	21	3,229	No	No
Indeterminate	Indeterminate	28	54,226	Yes	No
Indeterminate	Indeterminate	24	6,146	Yes	No
NA	Indeterminate	6	2,483	No	No
NA	Indeterminate	6	7,458	Yes	No
Indeterminate	Negative	28	22,484	Yes	No
Indeterminate	Negative	18	64,277	Yes	No
Indeterminate	Negative	16	2,278	No	No
Positive	Negative	27	6,941	Yes	No
Positive	Negative	28	2,174	Yes	No
NA	Negative	2	2,199	No	No
Indeterminate	Positive	26	1,173	No	No
Indeterminate	Positive	25	3,857	Yes	No
Positive	Positive	27	6,099	No	No
Positive	Positive	28	103,794	Yes	No

^aPt, patient; TX, transplant; NA, not available.

^bValganciclovir at 900 mg twice daily (renal function adjusted) until at least two consecutive whole-blood samples gave CMV DNA-negative results.